Correspondence Address : Dr. A wide array of materials have been used in the past as pulpotomy medicaments including calcium hydroxide, formocresol, and mineral trioxide aggregate. However, none of these are considered ideal as each has its own disadvantages. In the recent years, Biodentine has been considered a promising material for pulpotomy of primary molars owing to its superior physical and biological properties. This article describes a series of eight case reports on clinical and radiographic evaluation of primary molars treated with Biodentine pulpotomy with a follow-up of 3, 6, and 9 months. Users Online
|Published (Last):||4 April 2019|
|PDF File Size:||20.26 Mb|
|ePub File Size:||16.39 Mb|
|Price:||Free* [*Free Regsitration Required]|
Extensive decay in primary teeth remains an all too common problem often requiring pulp treatment as part of its management. Reviews have suggested that mineral trioxide aggregate MTA shows better outcomes than other materials although Biodentine a more recently developed calcium silicate cement has demonstrated good outcomes. The aim of this review was to compare the clinical and radiographic success of Biodentine compared to MTA.
Study selection and data extraction and risk of bias assessment was carried out independently by two reviewers. The Cochrane Collaboration tools was used to assess risk of bias. The main outcomes were clinical and radiographic success. Meta-analysis was performed for the success rate of Biodentine versus MTA at three time points 6, 12, and 18 months.
There is no superiority of one material over the other MTA or Biodentine. This result suggests the potential of Biodentine as pulpotomy medicament in primary teeth. Further randomized clinical trials of good quality, greater sample size, and longer follow-up time are necessary in order to confirm the results presented.
The recently published Cochrane review Dental Elf — 8 th June looked in detail at a wide range of pulp treatment techniques for the management of extensive decay in primary teeth. They found that the evidence suggested that MTA may be the most efficacious medicament and that further research should be undertaken on Biodentine enamel matrix derivative, laser treatment or Ankaferd Blood Stopper to confirm if they were acceptable second choice. The current review searched a broad range of databases and compares Biodentine and MTA.
The authors highlight that not all of the studies provided data at all time points with only 6 trials providing data at 12 months and 3 trials at 18 months.
Fewer that patients have been included in the studies to date so additional well conducted and reported trials involving larger sample sizes and of longer duration would be helpful. MTA and biodentine for primary teeth pulpotomy: a systematic review and meta-analysis of clinical trials. Clin Oral Investig. Pulp treatments in primary teeth. Email Not published. In addition to all of the other problems that come with extensive interproximal decay is mesial migration of teeth into the areas where proximal enamel has been lost.
The resultant arch length loss can compromise succedaneous tooth eruption in the buccal segments. Results 9 studies were included. No differences were found between the clinical and radiographic success rates at any of the 3 time points tested. Comments The recently published Cochrane review Dental Elf — 8 th June looked in detail at a wide range of pulp treatment techniques for the management of extensive decay in primary teeth. Logging In Profile cancel Sign in with Twitter Sign in with Facebook.
Arnold J. Malerman, DDS. View November 24, Free trial Close.
The Dental Elf
Metrics details. The objective of this clinical study was to prospectively compare the clinical and radiographic success rates of Biodentine TM pulpotomies versus formocresol pulpotomies in children vital primary molars. A randomized, split—mouth study design was used with a sample of 37 healthy children aged 4— to 8—year—old. A total of 56 pairs teeth of carious primary teeth, 1 pair per child, were selected for treatment. One tooth from each pair was randomly assigned to either the Biodentine TM pulpotomy group or the formocresol pulpotomy group. Children were followed—up at 3, 6 and 12 months for clinical evaluation and at 6 and 12 months for radiographic evaluation. Data were collected, tabulated and analyzed using Fisher exact and McNemar tests.